AngioDynamics (NASDAQ:ANGO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a buy rating in a report issued on Saturday.

A number of other equities research analysts have also recently commented on ANGO. Canaccord Genuity Group increased their target price on shares of AngioDynamics from $17.00 to $18.00 and gave the company a “buy” rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.33.

AngioDynamics Stock Up 1.5%

ANGO opened at $13.34 on Friday. The firm’s fifty day simple moving average is $12.23 and its two-hundred day simple moving average is $10.74. AngioDynamics has a 52-week low of $8.27 and a 52-week high of $13.99. The company has a market cap of $549.61 million, a price-to-earnings ratio of -17.10 and a beta of 0.49.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.02. AngioDynamics had a negative net margin of 10.67% and a negative return on equity of 3.16%. The firm had revenue of $75.71 million for the quarter, compared to analyst estimates of $72.69 million. During the same period last year, the company posted ($0.11) EPS. AngioDynamics’s quarterly revenue was up 12.1% compared to the same quarter last year. AngioDynamics has set its FY 2026 guidance at -0.330–0.230 EPS. On average, research analysts forecast that AngioDynamics will post -0.37 EPS for the current year.

Insiders Place Their Bets

In other AngioDynamics news, CEO James C. Clemmer acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, October 9th. The stock was purchased at an average cost of $11.15 per share, with a total value of $111,500.00. Following the transaction, the chief executive officer owned 882,529 shares of the company’s stock, valued at $9,840,198.35. This trade represents a 1.15% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Lawrence T. Weiss bought 10,000 shares of the firm’s stock in a transaction on Tuesday, October 21st. The stock was bought at an average cost of $11.81 per share, for a total transaction of $118,100.00. Following the transaction, the senior vice president directly owned 93,597 shares of the company’s stock, valued at $1,105,380.57. The trade was a 11.96% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders acquired 20,890 shares of company stock worth $239,532 in the last 90 days. Company insiders own 6.00% of the company’s stock.

Hedge Funds Weigh In On AngioDynamics

Several large investors have recently made changes to their positions in the stock. Divisadero Street Capital Management LP increased its holdings in AngioDynamics by 8.3% in the 3rd quarter. Divisadero Street Capital Management LP now owns 3,678,125 shares of the medical instruments supplier’s stock valued at $41,085,000 after purchasing an additional 282,695 shares during the last quarter. Systematic Financial Management LP boosted its position in shares of AngioDynamics by 0.5% during the second quarter. Systematic Financial Management LP now owns 2,509,906 shares of the medical instruments supplier’s stock worth $24,898,000 after buying an additional 12,617 shares during the period. Vanguard Group Inc. grew its stake in shares of AngioDynamics by 8.7% in the first quarter. Vanguard Group Inc. now owns 2,492,563 shares of the medical instruments supplier’s stock valued at $23,405,000 after buying an additional 199,944 shares in the last quarter. Armistice Capital LLC raised its holdings in shares of AngioDynamics by 140.1% in the 1st quarter. Armistice Capital LLC now owns 2,094,000 shares of the medical instruments supplier’s stock valued at $19,663,000 after buying an additional 1,222,000 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of AngioDynamics by 28.1% in the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock valued at $20,030,000 after buying an additional 393,682 shares during the period. 89.43% of the stock is currently owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.